Another study in breast cancer cells has shown that PART1 silencing improves the sensitivity of these cells to cisplatin, promotes cell apoptosis, and decreases expression proteins contributing in drug resistance (Lou et al., 2020). The gene discussed is PART1; the disease is breast cancer.